Tag:

AstraZeneca

Latest Headlines

Latest Headlines

UPDATED: Pfizer pitches $101B megamerger to struggling AstraZeneca--Report

Pfizer has reportedly made overtures offering to buy the struggling pharma giant AstraZeneca for $101 billion, setting the stage for what could be the first megamatchup in pharma land in years.

Pfizer, AstraZeneca back a new strategy for cancer drug R&D

A pair of pharma giants have partnered with a prominent cancer research charity in the U.K. on an innovative new approach to testing targeted oncology therapies, building on the country's national program for tumor testing in a way that may help make it a global center of cancer R&D.

GlaxoSmithKline joins a Big Pharma immuno-oncology R&D alliance

GlaxoSmithKline is taking a berth next to teams from AstraZeneca, Pfizer and Johnson & Johnson in an ambitious alliance of industry giants aimed at discovering some new products in the red-hot cancer R&D field.

Which brands grab the drug-spending title? AbbVie's Humira, AZ's Nexium lead the way

Which drugs cost U.S. health plans the most? Take a look at this year's iteration of Express Scripts' annual Drug Trend Report, and you'll find commentary on drug prices, the pharma industry, and American society. Not to mention a hint at which brands are best at getting themselves noticed.

AstraZeneca expands StarPharma deal for cancer drug delivery tech

AstraZeneca has expanded its deal with Australia's StarPharma, originally inked in September 2012, to use its drug delivery technology with a cancer drug in AstraZeneca's pipeline.

AstraZeneca cozies up to MRC scientists amid an R&D rethink

AstraZeneca isn't due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery.

Pfizer gets FDA green light for Nexium OTC launch as AZ braces for competition

AstraZeneca has been pulling out all the stops in trying to preserve blockbuster Nexium's revenues for as long as it can. Now, the FDA has approved an over-the-counter version of the drug--but thanks to a 2012 agreement, those sales are on their way to Pfizer.

AstraZeneca looks to China for kidney disease R&D

AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China's aging population. 

AstraZeneca takes control of its destiny in Japan with buyout

Japan is the second largest drug market after the U.S., and Western drugmakers are giving it new attention as growth slows elsewhere. AstraZeneca has upped its bet there, paying Sumitomo Chemical about $102 million to buy full control of its Japanese subsidiary AstraZeneca KK.

AstraZeneca, Pfizer say direct-delivery programs can win with patients

Time is running out before generics descend on Nexium, the stomach drug that rakes in nearly $4 billion a year for AstraZeneca. And in an effort to conserve sales, the British drugmaker is going where it's gone once before: a direct-to-patient delivery program it hopes will keep customers in its grasp.